Robotic sentinel lymph node dissection experiences in endometrial cancer at our tertiary cancer treatment institution.

Erkan ��im��ek, Sad��k G��nd��z, ��zge Akdeniz Y��ld��z, Zinar Serhano��lu, Levent Ya��ar
Author Information
  1. Erkan ��im��ek: University of Health Sciences Turkey, Bak��rk��y Dr. Sadi Konuk Training and Research Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology - ��stanbul, Turkey. ORCID
  2. Sad��k G��nd��z: University of Health Sciences Turkey, Bak��rk��y Dr. Sadi Konuk Training and Research Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology - ��stanbul, Turkey. ORCID
  3. ��zge Akdeniz Y��ld��z: University of Health Sciences Turkey, Bak��rk��y Dr. Sadi Konuk Training and Research Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology - ��stanbul, Turkey. ORCID
  4. Zinar Serhano��lu: K��r��khan State Hospital, Gynecology and Obstetrics Clinic - Antakya, Turkey. ORCID
  5. Levent Ya��ar: University of Health Sciences Turkey, Bak��rk��y Dr. Sadi Konuk Training and Research Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology - ��stanbul, Turkey. ORCID

Abstract

OBJECTIVE: In endometrial cancer surgery, sentinel lymph node dissection is used instead of staging surgery, particularly in advanced disease that is limited to the uterus. The aim of this study is to evaluate our practice of robotic sentinel lymph node dissection, which is applied to endometrial cancer patients in our tertiary cancer treatment center, according to the current literature, and to share our own data.
METHODS: Included in our analysis are patients who underwent robotic sentinel lymph node dissection for endometrial cancer utilizing indocyanine green in our center between January 2018 and January 2024.
RESULTS: In all, of the 93 endometrial carcinoma patients who underwent sentinel lymph node biopsy, 63 were classified as low-risk, while 30 were high-risk according to the European Society of Gynaecological Oncology and National Comprehensive Cancer Network guidelines. We found sentinel lymph nodes in both low-risk and high-risk patients, with an overall sensitivity of 96.32% (95% confidence interval [CI], 85.12-99.71), specificity of 100% (95%CI, 92.20-99.8), negative predictive value of 96.72% (95%CI, 87.03-99.89), and negative likelihood ratio of 0.06 (95%CI, 0.01-0.36).
CONCLUSION: After evaluating our data retrospectively, we determined that we were compatible with the current literature.

References

  1. J Minim Invasive Gynecol. 2021 Aug;28(8):1531-1535 [PMID: 33373726]
  2. Int J Gynecol Cancer. 2020 Mar;30(3):339-345 [PMID: 32075897]
  3. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  4. Gynecol Oncol. 2019 Jun;153(3):676-683 [PMID: 30952370]
  5. Arch Gynecol Obstet. 2024 Jun;309(6):2829-2832 [PMID: 38578545]
  6. J Clin Med. 2020 Nov 28;9(12): [PMID: 33260511]
  7. Lancet Oncol. 2017 Mar;18(3):384-392 [PMID: 28159465]
  8. J Natl Compr Canc Netw. 2023 Feb;21(2):181-209 [PMID: 36791750]
  9. Transl Cancer Res. 2022 Jul;11(7):2217-2224 [PMID: 35966308]
  10. Ann Surg Oncol. 2023 Nov;30(12):7653-7662 [PMID: 37633852]
  11. JAMA Surg. 2021 Feb 1;156(2):157-164 [PMID: 33175109]
  12. CA Cancer J Clin. 2022 Jan;72(1):7-33 [PMID: 35020204]
  13. Eur J Cancer. 2019 Jul;116:77-85 [PMID: 31181536]
  14. Arch Gynecol Obstet. 2019 Jun;299(6):1667-1672 [PMID: 30927059]
  15. J Obstet Gynaecol Can. 2021 Oct;43(10):1136-1144.e1 [PMID: 33984524]
  16. Int J Gynecol Cancer. 2021 Jan;31(1):12-39 [PMID: 33397713]
  17. Front Oncol. 2024 Apr 03;14:1391267 [PMID: 38634055]
  18. Gynecol Oncol. 2023 Jun;173:41-48 [PMID: 37075495]
  19. Gynecol Oncol. 2017 Oct;147(1):120-125 [PMID: 28751118]
  20. Gynecol Oncol. 2021 Jul;162(1):38-42 [PMID: 33906784]

MeSH Term

Humans
Female
Endometrial Neoplasms
Robotic Surgical Procedures
Middle Aged
Sentinel Lymph Node Biopsy
Aged
Tertiary Care Centers
Retrospective Studies
Adult
Sensitivity and Specificity
Sentinel Lymph Node
Lymph Node Excision
Indocyanine Green
Neoplasm Staging
Aged, 80 and over
Lymphatic Metastasis

Chemicals

Indocyanine Green

Word Cloud

Created with Highcharts 10.0.0cancersentinellymphendometrialnodedissectionpatients95%CIsurgeryrobotictertiarytreatmentcenteraccordingcurrentliteraturedataunderwentJanuarylow-riskhigh-risk96negative0OBJECTIVE:usedinsteadstagingparticularlyadvanceddiseaselimiteduterusaimstudyevaluatepracticeappliedshareMETHODS:Includedanalysisutilizingindocyaninegreen20182024RESULTS:93carcinomabiopsy63classified30EuropeanSocietyGynaecologicalOncologyNationalComprehensiveCancerNetworkguidelinesfoundnodesoverallsensitivity32%95%confidenceinterval[CI]8512-9971specificity100%9220-998predictivevalue72%8703-9989likelihoodratio0601-036CONCLUSION:evaluatingretrospectivelydeterminedcompatibleRoboticexperiencesinstitution

Similar Articles

Cited By